Rentschler R, Burgess M A, Byers R
Cancer. 1977 Aug;40(2):619-24. doi: 10.1002/1097-0142(197708)40:2<619::aid-cncr2820400205>3.0.co;2-e.
From 1950 through 1975, 671 patients with malignant major salivary gland neoplasms were referred to M. D. Anderson Hospital and Tumor Institute. Thirty-six patients with advanced local or metastatic disease subsequently underwent 62 evaluable trials with a variety of chemotherapeutic agents, either alone or in combination. Six patients achieved a partial response, with a median duration of 3 months. Ten additional patients had stable disease for 2 or more months. Anthracyclines appeared to be the most effective agents in this study, with three partial responses of six evaluable trials. The longest partial response (10 months) occurred in a patient receiving combination chemotherapy plus BCG immunotherapy. Pulmonary metastases were most commonly responsive to chemotherapy. The median intervals from diagnosis to death or to last follow-up and from initiation of chemotherapy to death or to last follow-up were 30 months and 6 months, respectively. Further therapeutic trials are necessary before response rates to single chemotherapeutic agents or combinations can be accurately assessed. In view of the poor prognosis of patients with recurrent disease, postoperative adjuvant studies with chemoimmunotherapy in patients with a high risk of recurrence are planned.
1950年至1975年期间，671例患有恶性大唾液腺肿瘤的患者被转诊至MD安德森医院和肿瘤研究所。36例患有局部晚期或转移性疾病的患者随后接受了62次可评估的试验，使用了多种化疗药物，单独或联合使用。6例患者获得部分缓解，中位缓解持续时间为3个月。另外10例患者病情稳定2个月或更长时间。在本研究中，蒽环类药物似乎是最有效的药物，在6次可评估的试验中有3例部分缓解。最长的部分缓解（10个月）发生在一名接受联合化疗加卡介苗免疫治疗的患者身上。肺转移最常对化疗有反应。从诊断到死亡或最后一次随访以及从开始化疗到死亡或最后一次随访的中位间隔分别为30个月和6个月。在能够准确评估单一化疗药物或联合化疗的缓解率之前，有必要进行进一步的治疗试验。鉴于复发疾病患者的预后较差，计划对复发风险高的患者进行术后化疗免疫辅助研究。
